医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CDISC President and CEO Appoints Shannon Labout Interim Chief Standards Officer

2017年06月09日 PM11:17
このエントリーをはてなブックマークに追加


 

AUSTIN, Texas

Today, David R. Bobbitt, President and CEO at Clinical Data Interchange Standards Consortium (CDISC), appointed Shannon Labout CDISC’s Interim Chief Standards Officer. A collaborative leader, dedicated educator, and Certified Clinical Data Manager (CCDM), Ms. Labout has a proven track record of creating, leading and growing successful organizations in clinical data management, standards implementation and training. In her new role, she will guide the future of standards development, working with CDISC leadership, partners, members and volunteer teams. She will also continue to serve as CDISC’s VP of Education.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170609005441/en/

Shannon Labout, Interim Chief Standards Officer, CDISC (Photo: Business Wire)

Shannon Labout, Interim Chief Standards Officer, CDISC (Photo: Business Wire)

“I am excited that Shannon is taking this key role,” Mr. Bobbitt commented. “Now that CDISC standards are required by the FDA and PMDA, endorsed by China FDA, and requested for use by the European Innovative Medicines Initiative (IMI), CDISC is at a critical inflection point. Shannon’s leadership will ensure we do what is necessary to support our volunteer teams while building sustainable clinical data standards.”

“Shannon has a great ability to motivate her team and leverage each individual’s strengths, which is difficult enough with a dedicated pool of resources, so it is even more impressive that she is able to accomplish this with a team primarily consisting of volunteers,” said Lauren Shinaberry, Associate Director, Data Standards, AbbVie and CDISC Volunteer.

“As an implementer of CDISC standards since 1999, a volunteer and instructor for eleven years, and member of CDISC staff and leadership for over seven years, I am deeply aware of the challenges and opportunities facing CDISC and our community,” added Ms. Labout. “It is a great privilege to be able to influence the future of the CDISC organization in this new role.”

CDISC began as a grass roots initiative in 1997 in response to the need to better structure and improve the quality and consistency of data in clinical research. Volunteers came together to create workgroups and share the idea of CDISC, building awareness and generating support. Ms. Labout has served as a CDISC staff member since 2010 and a volunteer since 2006.

About CDISC – CDISC is a 501(c)(3) global, non-profit organization that develops data standards to foster smarter research and enable connections to healthcare. CDISC standards allow data to speak the same language, by providing common formats for data collection, data sharing and data analyses to make the most of the valuable information offered by patients participating in research studies around the globe, enabling researchers to discover new treatments, find breakthroughs, and unlock cures. CDISC standards are required for regulatory submissions to the U.S. FDA and Japan PMDA, are endorsed by the China CFDA, and are requested for use by the European Innovative Medicines Initiative (IMI). The suite of CDISC standards is freely available on the CDISC website.

CDISC is funded through the generous support of over 400 member organizations from pharmaceutical, biotech, clinical research organizations, regulatory agencies, academia, and healthcare, as well as through grants, authorized CDISC Education courses, events and charitable contributions. To find out more about how to support CDISC and get involved, please visit www.cdisc.org and www.unlockcures.org.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170609005441/en/

CONTACT

CDISC
Ann P. White, 512-363-5826
Senior Communications Manager
awhite@cdisc.org

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
  • New Data Shows Previously Allergic Children Still Able to Tolerate Peanut Four Years after Treatment with a Novel Immunotherapy Licensed by Prota Therapeutics
  • Mannatech Australia Makes the Morning Healthier with New Nutrient-Rich Coffee
  • CDISC Releases Therapeutic Area User Guide to Assist in Discovery of New Treatments for Prostate Cancer
  • ドバイ保険局がマシモ・ペイシェント・セーフティーネットを導入